Biographical Sketch
Herbert P. Wiedemann, MD, MBA, is Chairman of the Cleveland Clinic Respiratory Institute as well as Chairman of the Department of Pulmonary, Allergy & Critical Care Medicine, a position he has held since 1991. Dr. Wiedemann also served a five-year term on Cleveland Clinic's Board of Governors (2001-2006).
He is board-certified in internal medicine, pulmonary disease, and critical care medicine, Dr. Wiedemann's clinical interests are intensive care medicine (including acute respiratory distress syndrome and sepsis) and the evaluation of dyspnea (including cardiopulmonary exercise testing).
Dr. Wiedemann has been the recipient of many awards including The Best Doctors in America, America's Top Doctors, Who's Who in Medicine and Healthcare, and Who's Who in America. Dr. Wiedemann has participated in several large multicenter trials of new therapies for acute respiratory distress syndrome (ARDS) and sepsis, and he served as principal investigator for three of these trials.
In addition, Dr. Wiedemann is a journal reviewer for many peer-reviewed publications including New England Journal of Medicine, Annals of Internal Medicine, Chest, European Respiratory Journal, and Journal of Intensive Care Medicine. He is a member or fellow of the American College of Chest Physicians, the American College of Critical Care Medicine and the American College of Physicians. Dr. Wiedemann also has taught as a visiting professor at many national and international universities.
After receiving his B.S degree from Yale, and medical degree from Cornell University College of Medicine in New York City, Dr. Wiedemann completed his internship and residency in internal medicine at the University of Washington Medical Center in Seattle, where he also served as chief medical resident. He completed his fellowship in pulmonary and critical care medicine at Yale University in Haven Hospital in Connecticut. Dr. Wiedemann has also received an M.B.A. degree from the Yale University School of Management.
Specialty Interests
acute lung injury, exercise testing, fiberoptic bronchoscopy, intensive care (including adult respiratory distress syndrome and sepsis), interstitial lung disease, Lung Cancer, pleural effusions
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate
with the pharmaceutical or medical device industries
to help develop medical breakthroughs or provide
medical education about recent trends. The
collaborations are reviewed as part of the Cleveland
Clinic’s procedures. The Cleveland Clinic publicly
discloses payments to its physicians and scientists
for speaking and consulting of
$5,000 or more per year, and any equity, royalties,
and fiduciary relationships in companies with which
they collaborate. In publicly disclosing this
information, the Cleveland Clinic tries to provide
information as accurately as possible about its
doctors’ connections with industry and those of their
immediate family members. As of 7/31/2008, Dr.
Wiedemann has reported the financial relationships
with the companies listed below. Patients should feel
free to contact their doctor about any of the
relationships and how the relationships are overseen
by the Cleveland Clinic. To learn more about the
Cleveland Clinic’s policies on collaborations with
industry and innovation management, go to
our Integrity in Innovation page.
Consulting. Dr. Wiedemann receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:
Agennix
Eisai Medical Research Inc.
Takeda
Equity. Dr. Wiedemann owns stock or stock options in the following companies for activities as a founder, inventor, or consultant:
Advanced Life Sciences
